The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

March 23, 2020

Hui-Zi Chen, MD, PhD, discusses the use of immunotherapy in ES-SCLC and the work being done to identify mechanisms of resistance to frontline therapy.

March 23, 2020

Erin M. Bertino, MD, discusses the current treatment landscape and next steps in the EGFR-mutant NSCLC paradigm.

March 21, 2020

Terence M. Williams, MD, PhD, discusses the impact of the PACIFIC trial on stage III NSCLC and how the hunt for prognostic biomarkers is underway across the lung cancer paradigm.

March 20, 2020

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

March 20, 2020

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

March 10, 2020

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

March 07, 2020

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

March 07, 2020

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

March 04, 2020

Clara D. Bloomfield, MD, the 2015 Giants of Cancer® award winner for Myeloid Neoplasms and a revolutionary physician-scientist, died March 1 at the age of 77.

February 25, 2020

Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.

February 22, 2020

John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.

February 20, 2020

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

February 19, 2020

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

February 14, 2020

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

February 12, 2020

Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.

February 11, 2020

Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the use of PARP inhibitors in ovarian cancer.

February 07, 2020

Jonathan E. Brammer, MD, discusses the role of stem cell transplant in acute lymphoblastic leukemia.

February 07, 2020

Floor J. Backes, MD, discusses quality of life with PARP inhibitors for patients with ovarian cancer.

February 06, 2020

Alice S. Mims, MD, discusses her recommendations regarding holding therapy until molecular test results are received for symptomatic patients with acute myeloid leukemia.

February 05, 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).